Business Context and Reporting Period
This Form 8-K is filed by Big Rock Partners Acquisition Corp. (BRPA) on February 9, 2021. The filing reports on a proposed business combination between BRPA and NeuroRx, Inc. (NRX), wherein a wholly-owned subsidiary of BRPA will merge with NeuroRx. Additionally, the filing announces that NeuroRx reported preliminary results from the Phase 2b/3 trial of ZYESAMI (aviptadil) for patients with respiratory failure due to critical COVID-19.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either BRPA or NeuroRx. This document serves as a current report on material events rather than a periodic financial statement.
Material Changes and Events
- Merger Agreement: BRPA, NeuroRx, and Big Rock Merger Corp. have entered into an Agreement and Plan of Merger. Upon completion, NeuroRx will become a wholly-owned subsidiary of BRPA, and NeuroRx stockholders will become stockholders of BRPA.
- Clinical Trial Update: NeuroRx reported preliminary results from the Phase 2b/3 trial of ZYESAMI (aviptadil) in collaboration with Relief Therapeutics Holdings, AG. The specific clinical outcomes are detailed in the attached press release (Exhibit 99.1) and are not quantified in the body of this filing.
Guidance, Outlook, and Risks
The filing contains extensive forward-looking statements regarding the proposed transaction and the development of NeuroRx's drugs. Management cautions that actual results may differ materially from expectations due to significant risks and uncertainties, including:
- The ability to obtain regulatory approvals and complete the business combination.
- The risk of delisting from the Nasdaq Capital Market prior to or after the transaction.
- Disruption of NeuroRx's current operations due to the transaction.
- Costs associated with the business combination.
- Changes in laws, regulations, and the impact of the COVID-19 pandemic.
Investors are urged to read the Registration Statement on Form S-4, which includes the proxy statement and prospectus, for detailed information on the proposed transactions.
Investor Verification Checklist
- Verify the specific preliminary clinical results of the ZYESAMI Phase 2b/3 trial by reviewing Exhibit 99.1 (Press Release) attached to this filing.
- Review the Registration Statement on Form S-4 for detailed terms of the merger, including exchange ratios and transaction costs.
- Confirm the status of the proposed business combination and any conditions precedent required for closing.
- Assess the risks related to the FDA approval process for aviptadil as detailed in the proxy statement.
- Monitor the listing status of BRPA securities on the Nasdaq Capital Market.